Tharimmune (NASDAQ:THAR) Earns Buy Rating from Analysts at Rodman & Renshaw

Equities research analysts at Rodman & Renshaw assumed coverage on shares of Tharimmune (NASDAQ:THAR) in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage set a “buy” rating and a $17.00 price target on the stock.

Tharimmune Stock Up 3.4 %

Shares of NASDAQ THAR traded up $0.07 during trading hours on Friday, reaching $2.10. The stock had a trading volume of 105,934 shares, compared to its average volume of 352,554. Tharimmune has a fifty-two week low of $1.84 and a fifty-two week high of $9.79. The firm has a 50-day moving average of $2.30 and a 200-day moving average of $3.03.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC bought a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune as of its most recent filing with the SEC. 1.16% of the stock is owned by hedge funds and other institutional investors.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).